Lilly's 48% Revenue Surge and Guidance Raise While the Stock Gets Sold

The market is still pricing Eli Lilly as a company being pulled down by pricing pressure, M&A charges, and a sluggish oral-GLP-1 launch. The cash-flow path says the business just reported 48% revenue growth, raised its full-year revenue outlook by $2.5 billion, and generated $13.4 billion in free cash flow over the trailing twelve months - up nearly 576% from a year earlier.

The quarter that matters

Revenue came in at $22.97 billion for Q2 2026, well above the roughly $20.5–$20.7 billion range the Street was working with. Adjusted earnings per share were $8.38 against consensus near $6.01. The reported number was lower - $7.94 - because of $3.03 per share in acquired in-process R&D charges from the M&A activity this quarter. Those charges are real cash outflows, but they're lumpy and front-loaded; they don't reflect the operating engine.

The real story is volume. Lilly sold 60% more product globally year-over-year. In the U.S., volume rose 37%, with realized prices down only 3%. Outside the U.S., volume surged 113%, with realized prices declining 36% - largely because Mounjaro was added to China's national insurance list. Volume growth is vastly outpacing price erosion. That's the mechanism: lower prices pull more prescriptions through the system, and the volume effect dominates. CEO Dave Ricks laid this out in April, expecting global GLP-1 patients to grow from roughly 20 million at the end of 2025 to 30 million by year-end.

Mounjaro worldwide revenue was $9.94 billion, up 91%, well above the ~$9.0 billion Street expected. International Mounjaro sales alone jumped 172%. Zepbound U.S. revenue hit $4.93 billion, up 44%, beating the ~$4.7 billion estimate. The oral pill, Foundayo, brought in $98 million in its first full quarter of revenue - below the ~$103 million estimate, but this is a launch datapoint, not a verdict. Foundayo is competing against Novo Nordisk's oral Wegovy, which shipped first, and Lilly is still ramping its distribution channels and consumer advertising.

Guidance is the number that moves the trade

Lilly raised full-year revenue guidance to $85–$87 billion, up from the $82–$85 billion range set in Q1. That's a $2.5 billion midpoint increase. The adjusted EPS range was lowered to $35.50–$36.50, down from $35.50–$37.00, but only because the $3.03 per share in M&A charges from this quarter got folded into the outlook. Underneath, management raised the profit midpoint by $2.78 per share before those charges.

Arithmetic on the guidance: Q1 delivered $19.8 billion, Q2 delivered $23.0 billion. That leaves $42–$44 billion for the second half, or roughly $21–$22 billion per quarter. That's a meaningful step up from the roughly $20.7–$21.7 billion pace the old guidance implied. The second half has to accelerate. But the company also just announced Medicare's new obesity-drug coverage launching in July, which management expects to lift volume in H2. The guidance raise signals they're comfortable with that ramp.

The stock has been getting sold anyway

Shares are down roughly 10% over the past 20 days, pulling back from the $1,250 area to around $1,116. That sell-off happened while the business kept printing 40%+ quarterly growth, FCF exploded, and margins stayed at 48% operating and 83% gross. The tape pain has nothing to do with the operating story. It's about valuation anxiety - the stock has traded at a premium for a long time, and the M&A spending spree (Orna, Ajax, Centessa, Kelonia this quarter alone, plus three vaccine makers and a psychedelics deal) has left investors uneasy about what the balance sheet looks like.

The balance sheet numbers are worth staring at: total debt sits at $85.4 billion against $5.3 billion in cash, for a debt-to-equity ratio of 139%. That is high. But against $20.5 billion in trailing operating cash flow and $13.4 billion in free cash flow, the debt load is a manageable fraction of what the business generates. Free cash flow coverage alone would retire the entire net debt position in under three years at current run rates. The M&A spending is aggressive, but it's funded by cash generation, not by borrowing the business into trouble.

The financial bridge

The simplest target comes from the EPS bridge. Midpoint of the updated guidance is roughly $36 in adjusted earnings. At the current $1,116 price and roughly 940 million shares outstanding, the stock trades at about 31 times that figure. That's a meaningful discount from the 40x+ the market was willing to pay at recent highs, and well below the 62x forward PE implied by some consensus compilations that still carry outdated charge assumptions.

If the business hits the midpoint and the market restores even a 35x multiple - still below the historical premium this stock commanded during its growth inflection - the implied price is roughly $1,260. A 40x multiple, which would simply return the stock to its prior valuation range rather than re-rate it higher, points to $1,440. Both scenarios require the second-half revenue pace to hold - roughly $21–$22 billion per quarter - and the M&A integration to not drag margins below the current 48% operating level.

What could still break it

The pricing trajectory is the clearest risk. U.S. realized prices are already down 3% year-over-year, and excluding rebate adjustments that figure was closer to 9%. International prices are down 36%, though that's a one-time structural hit from China's insurance inclusion. If U.S. pricing pressure accelerates - from pharmacy-benefit-manager negotiations, cash-pay discounting, or Medicare's new obesity coverage pricing framework - and volume no longer fully compensates, the growth story gets thinner.

Foundayo's ramp is the second risk. $98 million in the first full quarter is a soft start. If the pill doesn't meaningfully accelerate through H2, it won't drag the company down, but it removes an optionality premium that was quietly priced in.

The third is M&A execution. Four acquisitions in one quarter, three more in the prior quarter, and another announced since. That's a lot of integration to pull off simultaneously. If acquired assets take longer to contribute or create accounting complexity that makes the already-messy EPS picture harder to follow, the stock's premium won't hold regardless of underlying growth.

The setup

The market is still anchoring to the old story - M&A charges, pricing fear, a pill that launched slowly - while the revenue growth, FCF expansion, and international volume acceleration point to something that hasn't changed direction. The 10% pullback over 20 days has created a wider gap between what the business is doing and what the tape reflects than we've seen in a while.

I'd frame the tripwire at $1,000. If the stock breaks below that level on a close, it would signal that the market has decided the M&A debt burden and pricing trajectory are structurally worse than the guidance implies. That would mean the thesis is wrong about volume compensating for price, and the position would need to come off. Above that, the financial bridge from $36 EPS and a multiple rerating back toward the low-30s-to-mid-30s range supports the $1,260–$1,440 zone over the next 12 months. Discipline over ego either way.